Showing results (111-120 of 223) with videos related to

Sort By:
Pageof 23
Multiple Sclerosis and Related Disorders|December 7, 2016
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-upCarrie M Hersh, Thomas E Love, Samuel Cohn, et al.
Annals of Clinical and Translational Neurology|December 31, 2024
Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitorsSaira Afzal, Yadi Li, Brittany Lapin, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 26, 2019
Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosisJenny Feng, Erik Offerman, Jian Lin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 13, 2014
Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical databaseDeborah M Miller, Nicolas R Thompson, Jeffrey A Cohen, et al.
Journal of Neurology|May 2, 2013
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMSJeffrey A Cohen, Frederik Barkhof, Giancarlo Comi, et al.
European Journal of Neurology|July 22, 2021
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 11, 2022
Perspectives and experiences with COVID-19 vaccines in people with MSJohn R Ciotti, Dana C Perantie, Brandon P Moss, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 15, 2019
Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantationLaura E Baldassari, Sarah M Planchon, Robert A Bermel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2018
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosisLauren Strober, John DeLuca, Ralph Hb Benedict, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 19, 2023
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosisEbtesam Alshehri, Jeffrey A Cohen, Daniel Ontaneda, et al.
Pageof 23